## RECEIVED CENTRAL FAX CENTER

DEC-04-2007 17:12

The Webb Law Firm

DEC 0 4 2007

P.003

PTO/SB/086 (05-07)

Approved for use through 11/30/2007. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		10056680	
	Filing Date		2002-01-25	
	First Named Inventor	Teddy	/ Kosoglou	
	Art Unit		1617	
( Not for submission under 37 CFR 1.99)	Examiner Name	San Ming R. Hui		
	Attorney Docket Num	per	CV 01492KUS (4686-045551)	

· ·				U.S.	PATENTS	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					
If you wisl	h to ac	dd additional U.S. Pater	t citatio	n information p	lease click the Add button.	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030119809		2003-06-26	Davis, Harry R.	
	2	20030119808		2003-06-26	Lebeaut, Alexandre P., et al.	
	3	20030119757		2003-06-26	Davis, Harry R.	
•	4	20030053981		2003-03-20	Davis, Harry R. et al.	
	5	20020183305		2002-12-05	Davis, Harry R. et al.	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

op ram tilm	F.004	
Application Number	10056680	
Filing Date	2002-01-25	
First Named Inventor	Teddy Kosoglou	
Art Unit	1617	
Examiner Name	San Ming R. Hui	
Attorney Docket Numi	per CV 01492KUS (4686-0	)45551)

	6	20020169134		2002-11-14		Davis, Harry R	•			
	7	20030109442		2003-06-12		Bisgaier, Charles L., et al.				
If you wist	n to ac	ld additional U.S. Publi	shed Ap	plication	citation	information p	lease click the Add	butto	n.	
				FOREIG	GN PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number³	Country Code <sup>2</sup> i		Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document	i	Pages Columns, Lines where Relevant Passages or Relevant Figures Appear	T6
	1									
If you wis	h to ac	id additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	buttor	)	
			NON	I-PATE	NY LITE	RATURE DO	CUMENTS			
Examiner Initials*	Cite No	I (DOOK MADAZINE IDUMA), SENAL SYMBOSIUM, CALAIOO, ELCI, QALE, DAGES(S), YORUMETISSUE MUMBER(S),							<b>T</b> 5	
	1	HAROLD BAYS, ET AL., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", Expert Opin, Pharmacother., Vol. 4, No. 11, pp. 1901-1938, (2003).								
	2	CESARE R. SIRTORI, "New Targets For Lipid Lowering And Atherosclerosis Prevention", Pharmac. Ther. Vol. 67, No. 3, pp. 433-447, (1995).								
	3	SANJAY KAUL, ET AL., "Intramural Delivery of Recombinant Apolipoprotein A-IMilano/Phospholipid Complex (ETC-216) Inhibits In-Stent Stenosis in Porcine Coronary Arteries", Circulation Vol. 107, pp. 2551-2554, (May 12, 2003).								
	4	GIULIA CHIESA, ET AL., "Apolipoprotein A-IMilano: Current Perspectives"; Curr. Opin. Lipidol, Vol. 14, pp. 159-163, (2003).								

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

DD 11.11			
Application Number		10056680	
Filing Date		2002-01-25	RECEIVED
First Named Inventor	Tedo	ly Kosoglou	CENTRAL FAX CENTER
Art Unit		1617	DEC 0 4 2007
Examiner Name	San	Ming R. Hui	DEO-0 1 2001
Attorney Docket Number		CV 01492KUS (46	686-045551)

	5	JOHN KASTELEIN, "What Future For Combination Therapies?", IJCP, pp. 45-50, (March 2003).									
	6	MARC EVANS, ET AL., "The Future Direction Of Cholesterol-Lowering Therapy"; Curr. Opin. Lipidol, Vol. 13, pp. 663-669, (2002).									
	7	CRAI Supp	CRAIG W. SPELLMAN, "Management of Diabetes In the Real World: Tight Control Of Glucose Metabolism", JAOA, Supplement 5, Vol. 103, No. 8, (August, 2003).								
,	8	ROBERT J. LIPSY, ET AL., "Optimizing Dyslipidemia Outcomes: A Novel Pharmacotherapeutic Pathway", JMCP, Vol. 9, No. 1, (January/February 2003).									
	9	PEDRO IGLESIAS, ET Al., "New Drugs For The Treatment Of Hypercholesterolaemia", Expert Opin, Investig. Drugs, Vol. 12, No. 11, pp. 1777-1789, (2003).									
If you wis	h to a	dd ad	ditional non-patent literature document citation information please click the Add t	outton	1						
			EXAMINER SIGNATURE								
Examiner Signature Date Considered											
*EXAMIN	NER: I	nitial if	reference considered, whether or not citation is in conformance with MPEP 609 remance and not considered. Include copy of this form with next communication	. Draw line through a to applicant.	Ī						
Standard S	T.3), <sup>3</sup> cumen	For Jap t by the	TO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the docume nanese patent documents, the indication of the year of the reign of the Emperor must precede the self appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is attached.	rial number of the patent doc	umont.						